Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification

Cell Death and Disease

Volumn 6, Issue , 2015, Pages

  Te Raa, G D ^a,b   Moerland, P D ^b   Leeksma, A C ^a,b   Derks, I A ^b   Yigittop, H ^c   Laddach, N ^c   Loden Van Straaten, M ^c   Navrkalova, V ^d   Trbusek, M ^d   Luijks, D M ^a,b   Zenz, T ^e   Skowronska, A ^f   Hoogendoorn, M ^g   Stankovic, T ^f   Van Oers, M H ^a,h   Eldering, E ^b,h   Kater, A P ^a,b,h  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MRC HOLLAND   (Netherlands)

^d MASARYK UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g MEDICAL CENTER LEEUWARDEN   (Netherlands)

^h Lymphoma and Myeloma Center Amsterdam (LYMMCARE)   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; PROTEIN P53; ANTINEOPLASTIC AGENT; ATM PROTEIN, HUMAN; DOXORUBICIN; FLUDARABINE; RNA; VIDARABINE;

ARTICLE; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DNA DAMAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REPRODUCIBILITY; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UPREGULATION; ANALOGS AND DERIVATIVES; BIOASSAY; DRUG RESISTANCE; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BIOLOGICAL ASSAY; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GAMMA RAYS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 84938842796     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.223     Document Type: Article

References (34)

1. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005; 106: 3175-3182.
2. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007; 25: 5448-5457.
3. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
4. Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 2012; 30: 4524-4532.
5. Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473-4479.
6. Stankovic T,Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26-29.
7. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814-822.
8. Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002; 99: 300-309.
9. Stankovic T, Hubank M, Cronin D, Stewart GS, Fletcher D, Bignell CR et al. Microarray analysis reveals that TP53-And ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinghuished by major differences in activating prosurvival responses. Blood 2004; 103: 291-300.
10. Mohr J, Helfrich H, Fuge M, Eldering E, Bühler A, Winkler D et al. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011; 117: 1622-1632.
11. Navrkalova V, Sebejova L, Zemanova J, Kminkova J, Kubesova B, Malcikova J et al. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. Haematologica 2013; 98: 1124-1131.
12. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26: 1458-1461.
13. Stankovic T, Skowronska A. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk Lymphoma 2014; 55: 1227-1239.
14. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010; 116: 4578-4587.
15. Mous R, Jaspers A, Luijks DM, Mellink CH, van Oers MH, Kater AP et al. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. Leukemia 2009; 23: 1352-1355.
16. Cox TF, Cox MAA. Multidimensional Scaling. Boca Raton: Chapman & Hall, 2nd edition. 2011.
17. Zent CS. Time to test CLL p53 function. Blood 2010; 115: 4154-4155.
18. Asslaber D, Pinon JD, Seyfried I, Desch P, Stöcher M, Tinhofer I et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 2010; 115: 4191-4197.
19. Johnson GG, Sherrington PD, Carter A, Lin K, Liloglou T, Field JK et al. A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res 2009; 69: 5210-5217.
20. Valganon M, Giraldo P, Agirre X, Larráyoz MJ, Rubio-Martinez A, Rubio-Felix D et al. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol 2005; 129: 53-59.
21. Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 2014; 123: 1021-1031.
22. te Raa GD, Derks IA, Luijks DM, van Laar J, Monsuur H, Oldreive C et al. SF3B1 mutations in CLL are equivalent to p53/ATM dysfunction and cause defective puma upregulation in response to chemotherapy. Blood (ASH Annual Meeting Abstracts) 8-11 December 2012. Abstract 711.
23. Carter A, Lin K, Sherrington PD, Atherton M, Pearson K, Douglas A et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia 2006; 20: 737-740.
24. Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R et al. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. Clin Cancer Res 2012; 18: 4191-4200.
25. Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 2009; 23: 1159-1163.
26. Best OG, Gardiner AC, Majid A, Walewska R, Austen B, Skowronska A et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008; 22: 1456-1459.
27. Prodosmo A, De AA, Nistico C, Gabriele M, Di Rocco G, Monteonofrio L et al. p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes. J Clin Invest 2013; 123: 1335-1342.
28. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
29. Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Famá R et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014; 123: 2139-2147.
30. Geisler CH, van T' Veer MB, Jurlander J, Walewski J, Tjønnfjord G, Itälä Remes M et al. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 2014; 123: 3255-3262.
31. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005; 19: 427-434.
32. Jethwa A, Hullein J, Stolz T, Blume C, Sellner L, Jauch A et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol 2013; 163: 496-500.
33. Vandesompele J, De PK, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
34. Eldering E, Spek CA, Aberson HL, Grummels A, Derks IA, de Vos AF et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 2003; 31: e153.